(a) These statements have not been evaluated by the Food and Drug Administration
We also present practical implications of these glucose-lowering agents for reducing the risk of adverse cardiovascular events and progressive renal comorbidity in patients with T2D and CVD
And when you start doing head banging, you go for a year or two on a clinical trial and then its negative, you say, What are we doing here? So I kind of thought that there was other opportunities and the excitement going on, for example, in cancer, in immune diseases, system diseases, many other things that just seem to be more stimulating that could use the new tools that we were starting to see
Her research focused on women, because the sample size of men taking GLP-1s was too small to draw significant conclusions, she said
With growing interest in peptide-based therapies, BPC-157 remains a key focus in regenerative medicine and injury recovery studies